HPS Pharmacies wish to advise that Phebra has given notice of an interruption to the supply of:
(ergometrine 0.5mg and oxytocin 5IU)
1mL injection x 5
Unprecedented demand has exhausted current supplies of Syntometrine® injection.
Phebra has obtained interim permission from the TGA to distribute Syntometrine® injection in packaging approved for distribution in New Zealand. This presentation is expected to be available next week, however may be insufficient to meet ongoing demand until supplies return to normal.
Although this New Zealand packaging does not display an Australian registration number, it does not require Special Access Scheme approval for supply. TGA authorisation for distribution permits supply of an unregistered product where there is an interruption to the supply of a registered product, and where there is a recognised medical need.
Please retain this notice in a prominent position, including in any other related business units, as a reminder for all staff members until supply returns to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or Phebra’s Medical Information Department on 1800 720 020 or email@example.com.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.